Realizing the Potential of Your Immune System to Conquer Cancer
SIRPant-M™ (SI-101)
Indication
NHL/Cutaneous T-Cell Lymphoma
Head & Neck Cancer
Solid Tumor TBD
- NHL/Cutaneous T-Cell Lymphoma
- Head & Neck Cancer
- Solid Tumor TBD
SIRPant-M™ (SI-101) is an autologous cancer-agnostic macrophage cell therapy manufactured using PhagoAct™, an advanced non-genetic method to activate and educate patients’ own macrophages for the recognition and elimination of cancerous cells.
As a monotherapy or in combination with other immuno-stimulatory modalities such as radiotherapy and immune checkpoint inhibitors, SIRPant-M™ acts by directly attacking cancerous cells, stimulating cancer neoantigen-specific cytotoxic T cells and antibodies, reducing immunosuppressive elements, and perpetuating a pro-inflammatory tumor microenvironment that favors cancer elimination.
SIRPant-M™ is currently being optimized for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (R/R NHL, SI-101). This therapy will be deployed as a therapeutic for other hard-to-treat cancers and solid tumors in follow-on studies.
By mobilizing other immune cells and promoting a multi-prong attack on cancer, SIRPant-M™ targets established tumors and achieves persistent and durable immune memory that resists cancer relapse.
SIRPant-T™ (SI-201)
Indication
Cancer TBD
- Cancer TBD
SIRPant-T™ (SI-201) is an autologous cancer-specific polyclonal T cell therapy manufactured using SIRPant-MTM macrophages to expand patient-isolated tumor-infiltrating lymphocytes (TIL) and peripheral blood T cells in ex vivo culture.
SIRPant-T™ (SI-201) will be used to treat a wide range of cancers, especially those associated with high mutational burdens and metastatic lesions.
SIRPant-T™ (SI-201) achieves therapeutic efficacy, as a monotherapy or in combination with other immuno-stimulatory modalities such as radiotherapy and immune checkpoint inhibitors, by locating, engaging, and killing cancerous cells. This results in systemic control of tumors and metastases with subsequent establishment of persistent and durable immune memory that resists cancer relapse.